10-K: AppYea Inc. Reports Increased Net Loss for Fiscal Year 2024, Cites Going Concern Uncertainty

AppYea Inc.'s Form 10-K reveals a significant increase in net loss for the fiscal year ended December 31, 2024, and raises substantial doubt about the company's ability to continue as a going concern.

Summary

• AppYea Inc., a digital health company focused on sleep apnea and snoring solutions, filed its Form 10-K for the year ended December 31, 2024.
• The company reported a net loss of $4.032 million for 2024, compared to a net loss of $1.817 million in 2023.
• The accumulated deficit as of December 31, 2024, was $10.358 million.
• The company's cash and cash equivalents totaled $79,000 as of December 31, 2024.
• The report expresses substantial doubt about AppYea's ability to continue as a going concern, citing recurring losses and limited operations.
• AppYea is developing wearable monitoring solutions for sleep apnea and snoring, including AppySleep, AppySleep LAB, and AppySleep PRO.
• The company plans to file a 510(k) FDA submission for AppySleep LAB in 2025 and pursue FDA approval for AppySleep PRO in 2026.
• AppYea relies on a licensing agreement with B.G. Negev Technologies and Applications Ltd. and Mor Research Application Ltd. for its core technology.
• The company faces competition from various sources in the snoring treatment and sleep apnea device markets.
• AppYea is subject to extensive government regulations, including FDA requirements for medical devices.
• The company's internal control over financial reporting was deemed ineffective as of December 31, 2024, due to a material weakness in segregation of duties.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with increasing losses, low cash reserves, and doubts about the company's ability to continue as a going concern. While there are some positive aspects related to product development, the overall sentiment is negative due to the financial instability and ineffective internal controls.

Positives

• AppYea is actively developing and commercializing products in the growing sleep apnea and snoring market.
• The company has a licensing agreement providing exclusive rights to key intellectual property.
• AppYea is pursuing FDA clearance for its AppySleep LAB device.
• The company has successfully piloted the AppySleep product on over 200 users and is preparing for sales in the second quarter of 2025.
• The company has established a logistical distribution facility in the US.

Negatives

• AppYea reported a significant increase in net loss for 2024.
• The company has a substantial accumulated deficit and limited cash reserves.
• The report expresses substantial doubt about AppYea's ability to continue as a going concern.
• AppYea's internal control over financial reporting was deemed ineffective.
• The company is dependent on raising additional capital to fund its operations.

Risks

• The company's ability to continue as a going concern is uncertain.
• AppYea faces intense competition in the health tech market.
• The company is subject to extensive government regulations, including FDA approval processes.
• The company's reliance on third parties for clinical trials and manufacturing poses risks.
• The company's technology development is headquartered in Israel, which is subject to political and military instability.
• The company's chairman may exert significant influence over its affairs.
• The company's stock is subject to penny stock rules, which may make buying or selling difficult.
• The company has not adopted various corporate governance measures, and as a result, stockholders may have limited protections against interested director transactions, conflicts of interest and similar matters.

Future Outlook

The company plans to file a 510(k) FDA submission for AppySleep LAB in 2025 and pursue FDA approval for AppySleep PRO in 2026. AppYea needs to raise additional operating capital in order to maintain operations as presently conducted and to realize its business plan.

Management Comments

• Management believes that funds on hand will enable the company to fund its operations and capital expenditure requirements through the end of the second quarter of 2025.
• Management concluded that the company's internal control over financial reporting was not effective on December 31, 2024.

Industry Context

The global anti-snoring treatment market is expected to grow significantly, reaching USD 8.6 billion by 2028. The global sleep apnea device market is also expanding, projected to reach USD 6.1 billion by 2028. AppYea operates in these competitive segments of the health tech market.

Comparison to Industry Standards

• ResMed is a competitor in the sleep apnea market, particularly in the area of home sleep testing.
• The document does not provide enough information to compare AppYea's financial performance to specific industry benchmarks or comparable companies.
• The document does not provide enough information to compare AppYea's product development timelines to specific industry benchmarks or comparable projects.

Management Changes

Legal Proceedings

• A lawsuit was filed against the company, its chairman, and other related parties in the Tel Aviv Magistrates Court, alleging breach of partnership and loan agreements.

Related Party Transactions

• SleepX entered into a patent license agreement with Nexense Technologies USA Inc., a related party.
• During 2021, SleepX borrowed from Nexense Technologies USA Inc. an aggregate amount of $47,623.
• The company converted outstanding amounts owed to its officers and directors for unpaid compensation into options of the company's common stock.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential cost reduction measures or delays in development programs.
• Customers may be impacted by potential delays in product development or commercialization.

Next Steps

• The company plans to file a 510(k) FDA submission for AppySleep LAB in 2025.
• The company plans to pursue FDA approval for AppySleep PRO in 2026.
• The company needs to raise additional operating capital in order to maintain operations as presently conducted and to realize its business plan.

Key Dates

Keywords

sleep apnea, snoring, digital health, wearable devices, FDA approval, financial results, going concern, internal control, licensing agreement, capital raise, AppYea, AppySleep